These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11679499)

  • 1. The role of enalapril in the prevention of ovarian hyperstimulation syndrome: a rabbit model.
    Gul TG; Posaci C; Caliskan S
    Hum Reprod; 2001 Nov; 16(11):2253-7. PubMed ID: 11679499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome.
    Morris RS; Wong IL; Kirkman E; Gentschein E; Paulson RJ
    Hum Reprod; 1995 Jun; 10(6):1355-8. PubMed ID: 7593495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit.
    Sahin Y; Kontaş O; Müderris II; Cankurtaran M
    Gynecol Endocrinol; 1997 Aug; 11(4):231-6. PubMed ID: 9272418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated interleukin-10 and sex steroid levels in peritoneal fluid of patients with ovarian hyperstimulation syndrome.
    Manolopoulos K; Lang U; Gips H; Braems GA
    Eur J Obstet Gynecol Reprod Biol; 2001 Dec; 99(2):226-31. PubMed ID: 11788177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pentoxifylline in the prevention of ovarian hyperstimulation syndrome in a rabbit model.
    Serin IS; Ozçelik B; Bekyurek T; Ozturk F; Koc N; Sahin Y
    Gynecol Endocrinol; 2002 Oct; 16(5):355-9. PubMed ID: 12587528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with buserelin, an agonist of gonadotropin-releasing hormone, suppresses ovarian hyperstimulation syndrome induced in rabbits.
    Oshima K; Suzuki K; Makita S; Yoshida Y
    Pharmacology; 2004 Nov; 72(3):184-9. PubMed ID: 15452367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
    Itskovitz-Eldor J; Kol S; Mannaerts B
    Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma prorenin response to human chorionic gonadotropin in ovarian-hyperstimulated women: correlation with the number of ovarian follicles and steroid hormone concentrations.
    Itskovitz J; Sealey JE; Glorioso N; Rosenwaks Z
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7285-9. PubMed ID: 3118364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series.
    Ando H; Furugori K; Shibata D; Harata T; Murata Y; Mizutani S
    Hum Reprod; 2003 Jun; 18(6):1219-22. PubMed ID: 12773449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?
    Caserta D; Lisi F; Marci R; Ciardo F; Fazi A; Lisi R; Moscarini M
    Gynecol Endocrinol; 2011 Nov; 27(11):862-6. PubMed ID: 21391759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human luteinizing hormone to trigger ovulation: randomized, controlled, dose-finding pilot study in ovulation induction.
    Pierson RA; Olatunbosun OA; Chizen DR; Saunders H; Loumaye E; De Moustier B
    J Reprod Med; 2014; 59(7-8):355-66. PubMed ID: 25098025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of follicular growth and production of a normal hormonal milieu in spite of using a constant low dose of luteinizing hormone in women with hypogonadotrophic hypogonadism.
    Shoham Z; Howles CM; Zalel Y; Weissman A; Insler V
    Hum Reprod; 1994 Mar; 9(3):431-6. PubMed ID: 7516348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of intravenous immunoglobulin in the prevention of severe ovarian hyperstimulation syndrome.
    Orvieto R; Achiron A; Margalit R; Ben-Rafael Z
    J Assist Reprod Genet; 1998 Jan; 15(1):46-9. PubMed ID: 9493066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI; Winter JS; Faiman C
    Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect and underlying mechanism of Bu-Shen-An-Tai recipe on ovarian apoptosis in mice with controlled ovarian hyperstimulation implantation dysfunction.
    Ma WW; Xiao J; Song YF; Ding JH; Tan XJ; Song KK; Zhang MM
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):401-406. PubMed ID: 28585136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.